We are dedicated to developing tomorrow’s drugs against oxidative stress, helping millions of people to prevent and treat serious kidney diseases and get a better life. ROSgard, our biological drug candidate, mimics the body’s own most powerful and universal defense system against oxidative stress. Designed with a natural “homing” to the kidneys, ROSgard prevents experimental kidney damage by cleaning, protecting and repairing the exposed cells and tissues.

Our early clinical trials programme consists of two phase I studies on healthy subjects and one phase Ib study on patients undergoing open-heart surgery.

Read more

CLINICAL STUDIES

ROSgard, our drug candidate, is designed to mimic the body's own defence system against oxidative stress by protecting, cleaning and repairing exposed cells and tissue.

Read more

ROSgard™

Acute kidney injury is a large market. The estimated annual value is USD 6.3 bn in the USA and GBP 500 mn in the UK.

Read more

INVESTOR RELATIONS

Video

See how ROSgard protects, cleans and repairs

ROSgard is designed to mimic the body's own defence system against oxidative stress by protecting, cleaning and repairing exposed cells and tissue.

Calendar & reports
News, reports & presentations
  • 13 Jun 2019 / Presentation

    Investor presentation, June 2019

    Read more
  • 21 May 2019 / Analysis

    Valuation of Monocl 2018

    Read more
  • 23 Aug 2018 / Analysis

    Valuation of AKI Monocl 2016

    Read more